A case of Anti-MDA5-Positive dermatomyositis after inactivated COVID-19 vaccine
Lili Yang
Department of Dermatology, Institute of Dermatology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
Department of Dermatology, Central Laboratory, Huzhou Central Hospital, Huzhou, China
Search for more papers by this authorTinglu Ye
Department of Dermatology, Institute of Dermatology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
Search for more papers by this authorHuanyu Liu
Department of Pathology, Peking University Shenzhen Hospital, Shenzhen, China
Search for more papers by this authorCong Huang
Department of Dermatology, Institute of Dermatology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
Search for more papers by this authorWeiwei Tian
Department of Dermatology, Institute of Dermatology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
Search for more papers by this authorCorresponding Author
Yueming Cai
Department of Rheumatology and Immunology, Peking University Shenzhen Hospital, Shenzhen, China
Correspondence
Yueming Cai, Department of Rheumatology and Immunology, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Email: [email protected]
Search for more papers by this authorLili Yang
Department of Dermatology, Institute of Dermatology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
Department of Dermatology, Central Laboratory, Huzhou Central Hospital, Huzhou, China
Search for more papers by this authorTinglu Ye
Department of Dermatology, Institute of Dermatology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
Search for more papers by this authorHuanyu Liu
Department of Pathology, Peking University Shenzhen Hospital, Shenzhen, China
Search for more papers by this authorCong Huang
Department of Dermatology, Institute of Dermatology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
Search for more papers by this authorWeiwei Tian
Department of Dermatology, Institute of Dermatology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China
Search for more papers by this authorCorresponding Author
Yueming Cai
Department of Rheumatology and Immunology, Peking University Shenzhen Hospital, Shenzhen, China
Correspondence
Yueming Cai, Department of Rheumatology and Immunology, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Email: [email protected]
Search for more papers by this authorOpen Research
DATA AVAILABILITY STATEMENT
Data available on request from the authors.
REFERENCES
- 1Cho K, Park S, Kim EY, Koyanagi A, Jacob L, Yon DK, et al. Immunogenicity of COVID-19 vaccines in patients with diverse health conditions: a comprehensive systematic review. J Med Virol. 2022; 94(9): 4144–55.
- 2Wu M, Karim M, Ashinoff R. COVID-19 vaccine-associated dermatomyositis. JAAD Case Rep. 2022; 23: 58–60.
- 3Gonzalez D, Gupta L, Murthy V, Gonzalez EB, Williamson KA, Makol A, et al. Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review. Rheumatol Int. 2022; 42(9): 1629–41.
- 4Carrasco L, Arthur A, Gaitan RJ, Case C. A rapidly progressive and rare illness: autoantibodies against melanoma diferentiation-associated protein 5 (anti-MDA5): amyopathic dermatomyositis with progressive interstitial lung disease that developed after covid-19 vaccine. Chest J. 2021; 160(4): A680–1.
- 5Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European league against rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017; 76(12): 1955–64.
- 6Wang G, Wang Q, Wang Y, Liu C, Wang L, Chen H, et al. Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. Front Immunol. 2021; 12:791348.
- 7Megremis S, Walker TDJ, He X, Ollier WER, Chinoy H, Hampson L, et al. Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis. Ann Rheum Dis. 2020; 79(10): 1383–6.
- 8Gouda W, Albasri A, Alsaqabi F, Al Sabah HY, Alkandari M, Abdelnaby H. Dermatomyositis following BNT162b2 mRNA COVID-19 vaccination. J Korean Med Sci. 2022; 37(5):e32.
- 9Xu A, Ye Y, Fu Q, Lian X, Chen S, Guo Q, et al. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology (Oxford). 2021; 60(7): 3343–51.
Citing Literature
